公开(公告)号：US20240345070A1

公开(公告)日：2024-10-17

申请号：US18580301

申请日：2022-07-21

申请人： Creatv MicroTech, Inc.

发明人： Daniel L. ADAMS ,  Cha-Mei TANG

IPC分类号： G01N33/50 ,  A61B5/00 ,  G01N33/574 ,  G16H10/40

CPC分类号： G01N33/5091 ,  A61B5/4848 ,  A61B5/7275 ,  G01N33/57492 ,  G16H10/40 ,  G01N2333/70532

摘要： Means for predicting treatment response in a subject having cancer are disclosed, where the predictions are based comparing the number and size of circulating cancer associated macrophage-like cells (CMLS) and circulating tumor cells (CTCs) found in biological samples at baseline and after induction of therapy, such as blood, from the subject.

公开(公告)号：US20240288430A1

公开(公告)日：2024-08-29

申请号：US18513107

申请日：2023-11-17

申请人： Genentech, Inc. ,  Foundation Medicine, Inc.

发明人： Craig Anthony CUMMINGS ,  Yan LI ,  Sarah Margaret SHAGAN ,  Erica Beth SCHLEIFMAN ,  David SHAMES ,  David FABRIZIO ,  Daniel LIEBER ,  Geoffrey Alan OTTO ,  Mark KENNEDY ,  Travis CLARK ,  Doron LIPSON ,  Jie HE ,  Shan ZHONG

IPC分类号： G01N33/574 ,  A61K39/00 ,  A61P35/00 ,  C07K14/735 ,  C07K16/28 ,  C12Q1/68 ,  C12Q1/6883 ,  G06F16/28 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70

CPC分类号： G01N33/574 ,  A61P35/00 ,  C07K14/70535 ,  C07K16/2827 ,  C07K16/2896 ,  C12Q1/68 ,  C12Q1/6883 ,  G01N33/57492 ,  G06F16/285 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/24 ,  C12Q2600/156 ,  G01N2333/70532 ,  G01N2800/52

摘要： The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.

公开(公告)号：US20240110917A1

公开(公告)日：2024-04-04

申请号：US18379036

申请日：2023-10-11

申请人： Mayo Foundation for Medical Education and Research

发明人： Luz M. Cumba-Garcia ,  Ian F. Parney

IPC分类号： G01N33/574 ,  G01N33/53 ,  G01N33/569 ,  G01N33/68

CPC分类号： G01N33/57488 ,  G01N33/53 ,  G01N33/56966 ,  G01N33/574 ,  G01N33/6863 ,  G01N2333/5428 ,  G01N2333/5437 ,  G01N2333/57 ,  G01N2333/70532 ,  G01N2333/70596

摘要： This document relates to methods and materials for identifying and/or treating mammals having cancer. For example, small extracellular vesicles (EVs), such as exosomes, obtained from a mammal suspected of having a cancer can be used to identify the mammal as having cancer and, optionally, the mammal can be treated.

公开(公告)号：US11674962B2

公开(公告)日：2023-06-13

申请号：US16041363

申请日：2018-07-20

申请人： Genentech, Inc. ,  Foundation Medicine, Inc.

发明人： Craig Anthony Cummings ,  Yan Li ,  Sarah Margaret Shagan ,  Erica Beth Schleifman ,  David Shames ,  David Fabrizio ,  Daniel Lieber ,  Geoffrey Alan Otto ,  Mark Kennedy ,  Travis Clark ,  Doron Lipson ,  Jie He ,  Shan Zhong

IPC分类号： C12Q1/68 ,  C12Q1/6883 ,  G01N33/574 ,  C07K16/28 ,  G16H50/50 ,  G16H50/30 ,  G16H50/70 ,  G16H50/20 ,  A61P35/00 ,  G06F16/28 ,  C07K14/735 ,  A61K39/00

CPC分类号： G01N33/574 ,  A61P35/00 ,  C07K14/70535 ,  C07K16/2827 ,  C07K16/2896 ,  C12Q1/68 ,  C12Q1/6883 ,  G01N33/57492 ,  G06F16/285 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/24 ,  C12Q2600/156 ,  G01N2333/70532 ,  G01N2800/52

摘要： The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.

公开(公告)号：US20190219585A1

公开(公告)日：2019-07-18

申请号：US16250721

申请日：2019-01-17

申请人： Merck Sharp & Dohme Corp.

发明人： Robert H. Pierce ,  Jennifer H. Yearley ,  Scott P. Turner ,  Belma Dogdas ,  Ansuman Bagchi

IPC分类号： G01N33/574 ,  G16H20/17 ,  G16H20/40 ,  G06T7/00 ,  C07K16/28 ,  C12Q1/6886 ,  G06T7/11 ,  G06T7/41 ,  G06T7/90 ,  G16B40/20

CPC分类号： G01N33/57492 ,  A61K2039/505 ,  C07K16/2818 ,  C07K2317/76 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/574 ,  G01N2333/70521 ,  G01N2333/70532 ,  G01N2800/52 ,  G06T7/0012 ,  G06T7/11 ,  G06T7/41 ,  G06T7/90 ,  G06T2207/10024 ,  G06T2207/10056 ,  G06T2207/10064 ,  G06T2207/20021 ,  G06T2207/30024 ,  G06T2207/30096 ,  G06T2207/30204 ,  G16B40/20 ,  G16H20/17 ,  G16H20/40

摘要： The present disclosure describes an IHC assay for detecting and quantifying spatially proximal pairs of PD-1-expressing cells (PD-1+ cells) and PD-Ligand-expressing cells (PD-L+ cells) in tumor tissue, and the use of the assay to generate proximity biomarkers that are predictive of which cancer patients are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods for testing tumor samples for the proximity biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

公开(公告)号：US20180306799A1

公开(公告)日：2018-10-25

申请号：US15738013

申请日：2016-06-23

申请人： Janssen Pharmaceutica NV

发明人： Linda A. Snyder ,  Gordon Powers ,  Manuel Alejandro Sepulveda ,  John D. Alvarez

IPC分类号： G01N33/574 ,  C07K16/28

CPC分类号： G01N33/57492 ,  A61K2039/505 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/70532

摘要： The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of detecting VISTA.

公开(公告)号：US20180306778A1

公开(公告)日：2018-10-25

申请号：US15767673

申请日：2016-10-11

申请人： Yale University

发明人： Lieping Chen ,  Jun Wang

IPC分类号： G01N33/50

CPC分类号： G01N33/505 ,  B01L3/5085 ,  B01L2300/0829 ,  G01N33/5023 ,  G01N2333/70532

摘要： The present invention provides Genome-Scale T Cell Activity Arrays (GS-TCAA), as well as methods of making these arrays and methods of using them to identify immune modulators.

公开(公告)号：US10071530B2

公开(公告)日：2018-09-11

申请号：US15815334

申请日：2017-11-16

申请人： Felix Sorkin

发明人： Felix Sorkin

IPC分类号： B29C70/54 ,  E04C5/12 ,  B28B7/30 ,  B28B1/14 ,  E04C5/16 ,  E04C5/07 ,  E04G21/12

CPC分类号： B29C70/541 ,  A61K31/337 ,  A61K39/39558 ,  A61K2039/505 ,  B28B1/14 ,  B28B7/303 ,  B28B7/306 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  E04C5/076 ,  E04C5/12 ,  E04C5/122 ,  E04C5/125 ,  E04C5/163 ,  E04G21/12 ,  E04G2021/128 ,  G01N33/57415 ,  G01N33/6866 ,  G01N33/6872 ,  G01N33/743 ,  G01N2333/57 ,  G01N2333/70532 ,  G01N2333/723 ,  G01N2800/7033

摘要： A pocket former may include a pocket former body, the pocket former body having an outer surface. The pocket former may further include a collapsible element, the collapsible element formed on the outer surface of the pocket former body. The collapsible element may extend radially outwardly from the pocket former body.

公开(公告)号：US09994637B2

公开(公告)日：2018-06-12

申请号：US15611134

申请日：2017-06-01

申请人： ZYMOGENETICS, INC.

发明人： Zeren Gao ,  Steven D. Levin ,  Janine M. Bilsborough ,  James W. West ,  Cameron S. Brandt ,  Eric M. Chadwick

IPC分类号： C07K16/28 ,  C07K14/47 ,  G01N33/50 ,  C12Q1/66 ,  G01N33/569 ,  C07K14/705 ,  A61K38/00 ,  A61K39/00

CPC分类号： C07K16/2827 ,  A61K38/00 ,  A61K2039/507 ,  C07K14/47 ,  C07K14/70532 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C12Q1/66 ,  G01N33/505 ,  G01N33/56972 ,  G01N2333/70532

摘要： The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.

公开(公告)号：US20180155429A1

公开(公告)日：2018-06-07

申请号：US15577673

申请日：2016-05-27

申请人： Bristol-Myers Squibb Company

发明人： Friedrich FINCKENSTEIN

IPC分类号： C07K16/28 ,  A61P35/00 ,  C07K16/30 ,  A61K9/00 ,  A61K39/395 ,  A61K45/06 ,  G01N33/574

CPC分类号： C07K16/2827 ,  A61K9/0019 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/3023 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/76 ,  G01N33/57423 ,  G01N2333/70532 ,  G01N2800/52

摘要： This disclosure provides a method for treating a subject afflicted with a PD-L1 positive non-squamous non-small cell lung cancer (NSCLC). The method comprises administering to the subject a therapeutically effective amount of an anti-PD-1 anti-body or anti-PD-L1 antibody. In some embodiments, the non-squamous NSCLC tumor has a PD-L1 expression of at least about 1%. In some embodiments, the subject is additionally administered another anti-cancer agent.